AstraZeneca’s asthma drug succeeds in late-stage oesophagitis trial
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic oesophagitis, a chronic inflammatory disorder of the oesophagus
Black News 
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic oesophagitis, a chronic inflammatory disorder of the oesophagus
